Positive Phase III Data on Sanofi's U300 - Analyst Blog

By
A A A

Sanofi ( SNY ) recently announced encouraging data from two phase III studies (EDITION I and EDITION II) evaluating its new insulin candidate, U300. Detailed data from both the studies are expected by the end of 2013.

The multi-center and open label EDITION I (n = 807) study compared the safety and efficacy of U300 and Lantus, another diabetes drug at Sanofi, in patients with type II diabetes using basal and mealtime insulin. U300 demonstrated similar blood sugar control with fewer night-time low blood sugar events as compared to Lantus.

Top-line data from the EDITION II study (n = 811) assessed the safety and efficacy of U300 versus Lantus in patients with type II diabetes using basal and oral antidiabetic treatments. Data from the study revealed that U300 was similar in efficacy to Lantus in terms of blood sugar reduction. However, fewer patients experienced night-time low blood sugar events with U300 as compared to Lantus.


Lantus, which generated sales of €1.3 billion in the first quarter of 2013, is one of the top-selling drugs at Sanofi. U300 on approval is expected to further strengthen Sanofi's product portfolio. Although Sanofi holds a strong position in the diabetes market, we note that the market is highly crowded with players like Novo Nordisk ( NVO ), Eli Lilly and Company ( LLY ) and AstraZeneca ( AZN ).

Sanofi carries a Zacks Rank #3 (Hold). We remain concerned about generic erosion confronting most of Sanofi's key drugs including Plavix, Avapro, Lovenox, Taxotere, Eloxatin and Xatral. The genericization of Avapro and Plavix is expected to negatively impact Sanofi's business net income by around €800 million in the first half of 2013.

Sanofi is looking to combat headwinds by containing operating costs. Additionally, new product launches should make significant revenue contributions in the upcoming quarters.

Companies that currently look attractive include Novo Nordisk, carrying a Zacks Rank #2 (Buy).



ASTRAZENECA PLC (AZN): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: Investing , Business , Stocks

Referenced Stocks: AZN , LLY , NVO , SNY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Spot the Dropout RRC
Spot the Dropout RRC                
Spot the Dropout MG
Spot the Dropout MG                 
Spot the Dropout IPC
Spot the Dropout IPC                
Spot the Dropout
Spot the Dropout                    

Stocks

Referenced

Most Active by Volume

40,901,345
  • $93.4365 ▼ 3.66%
26,588,997
  • $18.1468 ▼ 0.07%
17,431,371
  • $5.445 ▼ 1.89%
15,223,752
  • $122.01 ▼ 0.80%
14,317,983
  • $15.03 ▼ 1.18%
14,313,248
  • $31.255 ▲ 0.05%
14,135,911
  • $19.75 ▼ 0.60%
12,706,006
  • $36.26 ▼ 11.17%
As of 7/30/2015, 11:18 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com